News | Ablation Systems | May 11, 2016

Cardiac Ablation Does Not Reduce Atrial Fibrillation Risk for Wolff-Parkinson-White Patients

Study presented at HRS finds treating extra pathway has no impact on afib risk, regardless of age

May 11, 2016 — Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are just as likely as non-ablated patients to develop atrial fibrillation no matter what age they receive ablation, according to a new study.

The study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City also found that Wolff-Parkinson-White syndrome is a long-term cause of atrial fibrillation in addition to traditional risk factors such as obesity, high blood pressure, sedentary lifestyles and sleep apnea.

Wolff-Parkinson-White is a syndrome that results in an abnormal electrical pathway from the upper to the lower heart chambers. Patients with the syndrome can experience rapid abnormal heart rates when electricity bypasses the normal electrical system of the heart and uses the extra pathway.

Researchers at the Intermountain Medical Center Heart Institute initially set out to discover if catheter ablation reduces the long-term risk of atrial fibrillation and whether the patients' age at the time of the procedure affected their risk.

Their study consisted of previously collected data from three different groups: 872 Wolff-Parkinson-White patients who received ablation treatment between ages 22 and 57; 1,461 patients who were treated with medication; and 11,175 people who didn't have the syndrome.

The researchers found that no matter at which age an ablation is performed, adult patients with Wolff-Parkinson-White continue to have a life-long, significant risk of atrial fibrillation.

"When a lot of physicians encounter patients with Wolff-Parkinson-White and atrial fibrillation, they believe that if the accessory or extra pathway is treated and cured, then the risk of atrial fibrillation is removed," said Intermountain Medical Center Heart Institute cardiologist Jared Bunch, M.D., lead researcher of the study. "Our findings unfortunately do not confirm that belief and suggest otherwise."

The Intermountain Medical Center Heart Institute research team presented results of their study at the Heart Rhythm Society's 2016 Scientific Session, May 4-7, in San Francisco.

Catheter ablation is a technique that can cure the abnormal heart rhythms by cauterizing or freezing that extra pathway.

Atrial fibrillation is a common and irregular and rapid heart rate that occurs when the left ventricle stiffens to counteract high blood pressure while the left atrium dilates in response to higher pressures.

Blood clots commonly form in patients with atrial fibrillation, which makes it one of the most common causes of strokes.

Bunch said it's possible that Wolff-Parkinson-White patients also have an atrial myopathy, or abnormal heart muscle, that leads to long-term atrial fibrillation risk — independent of the extra pathway. He says close follow-up throughout the lives of patients with atrial fibrillation can help prevent risk of stroke.

The other members of the Intermountain Medical Center Heart Institute research team included Heidi May, Ph.D., MSPH; Tami Bair, RN; Brian Crandall, M.D.; Michael Cutler, DO, Ph.D., Victoria Jacobs, NP; Charles Mallender, M.D.; Jeffrey Osborn, M.D.; Peter Weiss, M.D., and John Day, M.D.

Intermountain Medical Center is the flagship facility for the Intermountain Healthcare system, which is based in Salt Lake City.

For more information: www.hrsonline.org

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init